![](https://news.europawire.eu/wp-content/uploads/2024/02/Almirall-HQ-144x144.jpg)
(IN BRIEF) Almirall S.A., a leading pharmaceutical company specializing in medical dermatology, has finalized an exclusive license agreement with Novo Nordisk for the development and commercialization of NN-8828, an IL-21 blocking monoclonal antibody. This innovative treatment holds potential for various … Read the full press release